CAS Medical Systems to Present at the 7th LHA Life Sciences & Medical Technologies Virtual Conference on June 28 Conference
Branford, Conn. June 26, 2012 CAS Medical Systems, Inc.
("CASMED") (NASDAQ: CASM)
today announced that Thomas Patton, Chief Executive
Officer, will present to investors as part of the 7th LHA
Life Sciences & Medical Technologies Virtual Conference on
Thursday, June 28, 2012 at 9:00 a.m. Eastern Time.
The presentation will be accessible live and for the next
90 days at the PrecisionIR event website
or at the Companys website www.casmed.com.
This day-long virtual conference event includes 30-minute
presentations with accompanying slides from seven industry
leaders, and begins at 9:00 a.m. Eastern Time.
About CASMED® - Monitoring What's Vital
CASMED is a leading developer and manufacturer of medical
devices for non-invasive patient monitoring. The
Company's FORE-SIGHT Absolute Cerebral Oximeter is the
only cerebral oximeter available with FDA clearance for
non-invasive, continuous measurement of absolute cerebral
tissue oxygen saturation for all patients, regardless of
age or weight. Direct monitoring of tissue oxygenation
provides a unique and powerful tool to alert clinicians to
otherwise unrecognized and dangerously low levels of
oxygenation of the brain and other tissues thereby allowing
them to intervene appropriately in the care of their
patients. In addition to FORE-SIGHT Oximeters and
accessories, the Company provides a line of bedside patient
vital signs monitoring products, proprietary non-invasive
blood pressure monitoring solutions for OEM use, neonatal
intensive care supplies, and service. CASMED products are
designed to meet the needs of a full spectrum of patient
populations worldwide, ranging from adults to pediatrics
and neonates.
For further information regarding CASMED, visit the
Company's website at www.casmed.com.
Company Contacts
Investors |
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future financial performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the result of on-going litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders and competitors and other risks detailed in the Company's Form 10-K for the year ended December 31, 2009 and other subsequent Securities and Exchange Commission filings.
Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.
distributed by |